NCT03482479View on ClinicalTrials.gov

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA)Churg-Strauss Syndrome (CSS)Giant Cell ArteritisGranulomatosis With PolyangiitisMicroscopic PolyangiitisPolyarteritis NodosaTakayasu Arteritis
Interventions
DRUG

Naltrexone Hydrochloride

Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks

OTHER

Placebo Comparator

A placebo tablet which matches the drug will be taken daily for 6 weeks.

Trial Locations (7)

15260

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester

84112

University of Utah, Salt Lake City

02115

Brigham and Women's Hospital, Boston

Unknown

St. Joseph's Healthcare, Hamilton

All Listed Sponsors
lead

University of Pennsylvania

OTHER